Edoxaban affects TRAP-dependent platelet aggregation.

Area of Science:

• Pharmacology
• Hematology
• Cardiology

Background:

• Edoxaban is an oral anticoagulant and direct factor Xa inhibitor.
• Its precise impact on platelet function requires further elucidation.
• Understanding these effects is crucial for managing anticoagulation therapy.

Purpose of the Study:

• To prospectively assess in vitro platelet function in patients with atrial fibrillation (AF) undergoing treatment with edoxaban.
• To quantify changes in platelet aggregation following edoxaban administration.

Main Methods:

• A single-center prospective study involving 20 patients with AF treated with edoxaban.
• Platelet aggregation was measured using light transmission aggregometry.
• Thrombin receptor activating peptide (TRAP)-induced aggregation was assessed at baseline and 2 hours post-dose.

Main Results:

• A statistically significant reduction in TRAP-induced platelet aggregation was observed 2 hours after edoxaban intake compared to baseline values (44.7 ± 32.03% vs. 73.3 ± 25.55%; p < 0.0001).
• No significant differences were noted between patient subgroups.
• TRAP-induced platelet aggregation is demonstrably reduced in non-valvular AF patients on edoxaban therapy.

Conclusions:

• Edoxaban administration leads to a significant decrease in platelet aggregation in patients with non-valvular atrial fibrillation.
• This finding contributes to a better understanding of edoxaban's pharmacological profile.
• Further research may explore the clinical implications of this antiplatelet effect.